title: Use of Oncotype DX in Women with Node-Positive Breast Cancer.
abstract: Women with early stage breast cancer frequently receive adjuvant chemotherapy to prevent recurrence; however, not all patients benefit. Recently, gene expression marker panels, such as Oncotype DX, that may better predict risk of breast cancer recurrence have become commercially available and are being used to guide treatment decisions. Oncotype DX analyzes the expression of 21 genes within a tumor to determine a recurrence score that corresponds to a specific likelihood of breast cancer recurrence within 10 years of the initial diagnosis, as well as response to adjuvant treatment. We examined the published literature on the analytic validity, clinical validity, and clinical utility of Oncotype DX in guiding adjuvant treatment decisions in women with lymph node-positive breast cancer.
authors: Program Director, CTEB, DCCPS, National Cancer Institute, NIH, Bethesda, MD;  Health Sciences Administrator, NCI, Bethesda, MD;  Genomic Pharmacoepidemiology, US National Cancer Institute and  Physician, Health Services Researcher.
authors: Naoko
authors: N
authors: Ishibe
authors: Sheri
authors: S
authors: Schully
authors: Andrew
authors: A
authors: Freedman
authors: Scott David
authors: SD
authors: Ramsey